Investment Rating - The report maintains an "Outperform" rating for JD Health International [2][5][17] Core Insights - JD Health's revenue for Q1 2025 reached a record high of RMB 16.65 billion, reflecting a year-over-year increase of 25.5% and a quarter-over-quarter increase of 0.8%, surpassing the full-year guidance [3][13] - The significant revenue growth is attributed to increased demand during the influenza season, growth in high-value original drugs, and higher sales of health supplements due to increased advertising investments [3][14] - The company achieved an operating profit of RMB 1.07 billion, a 119.8% increase, with an operating margin of 6.4%, leading to a net profit growth of 47.7% [3][14] - JD Health plans to focus on expanding its instant retail initiatives in 10 key cities, leveraging a hybrid B2C+O2O strategy to enhance customer engagement and operational efficiency [4][15] Financial Performance and Forecast - Revenue forecasts for FY25 and FY26 are RMB 66.6 billion and RMB 75.7 billion, representing year-over-year growth of 14.5% and 13.7% respectively [5][17] - Adjusted net profit projections are RMB 4.4 billion for FY25 and RMB 5.4 billion for FY26, with a corresponding P/E ratio of 26x and 21x [5][17] - The report emphasizes the company's strong fundamentals and maintains an optimistic outlook for the first half of 2025 and the full year [5][17]

Investment Rating - The report maintains an "Outperform" rating for JD Health International [2][18]. Core Insights - JD Health's Q1 2025 revenue reached a record high of RMB 16.65 billion, reflecting a year-over-year increase of 25.5% and a quarter-over-quarter increase of 0.8%, surpassing the full-year guidance [3][14]. - The revenue growth is attributed to increased demand during the influenza season, growth in high-value original drugs, and higher sales of health supplements due to increased advertising investments [15]. - The company achieved an operating profit of RMB 1.07 billion, a significant increase of 119.8%, with an operating margin of 6.4%, contributing to a net profit growth of 47.7% [15][18]. - JD Health plans to focus on self-operated on-demand drug delivery in 10 key cities in 2025, leveraging a hybrid B2C+O2O strategy to enhance customer stickiness and operational efficiency [4][16]. Financial Performance and Forecast - Revenue forecasts for FY25 and FY26 are RMB 66.6 billion and RMB 75.7 billion, representing year-over-year growth of 14.5% and 13.7% respectively [5][18]. - Adjusted net profit is projected at RMB 4.4 billion for FY25, reflecting a decrease of 7.3%, and RMB 5.4 billion for FY26, indicating an increase of 20.5% [5][18]. - The report estimates a P/E ratio of 26x for FY25 and 21x for FY26, indicating a favorable valuation based on the company's fundamentals [5][18]. Valuation - The DCF model estimates the equity value of JD Health at HKD 136.8 billion, corresponding to a target price of HKD 42.90 per share [8][9].

Core Viewpoint - JD Health reported strong Q1 2025 earnings, exceeding market expectations, leading to a significant stock price increase and highlighting its position as a leader in the pharmaceutical e-commerce sector [1] Group 1: Financial Performance - In Q1 2025, JD Health achieved revenue of 16.645 billion RMB, a year-on-year increase of 25.5% [1] - The operating profit was 1.071 billion RMB, representing a substantial year-on-year growth of 119.8% [1] - Adjusted net profit reached 1.3 billion RMB, up 73.4% from 754 million RMB in the same period last year [1] Group 2: Product and Service Innovation - JD Health solidified its position as the "first station for the online launch of new specialty drugs" by introducing several innovative medications in Q1 2025 [1] - The company launched multiple new drugs, including those from Pfizer and Esteve, expanding treatment options for patients [1] - JD Health made significant advancements in the medical AI sector, launching the "AI Jingyi" product system and achieving over 80% usage of AI services in online consultations [2] Group 3: Strategic Partnerships and Collaborations - JD Health deepened collaborations with leading health product companies like Tongrentang and Yanzhiwu, focusing on product innovation and digital supply chain [2] - At the fifth JD Health Partner Conference, the company established cooperation intentions for new products with nearly 50 global brands [2] - A strategic partnership with China National Pharmaceutical Group was announced, focusing on comprehensive supply chain and innovative marketing across various disease areas [3] Group 4: Market Expansion and Competitive Advantage - JD Health aims to enhance its offline capabilities to provide comprehensive services to suppliers, thereby increasing bargaining power [3] - The company's strong supply chain remains a core competitive advantage, contributing to robust growth in patented drugs, health products, and medical devices [3] - JD Health plans to prioritize self-built models in its offline expansion strategy before considering acquisition opportunities [3]

【恒生指数收盘涨2.3%，恒生科技指数涨2.13%】腾讯音乐涨约13%，京东健康涨约5%，理想汽车涨约 5%，百度集团涨约4%。 ...

Core Viewpoint - JD Health's stock price has surged significantly, driven by strong financial performance in Q1 2025, exceeding market expectations [2][7]. Financial Performance - In Q1 2025, JD Health reported revenue of 16.645 billion RMB, a year-on-year increase of 25.5% [4]. - Operating profit reached 1.071 billion RMB, a remarkable growth of 119.8% compared to the previous year [4]. - Non-IFRS operating profit was 1.308 billion RMB, reflecting a 73.4% increase year-on-year [4]. - The company's net profit for the period was 934 million RMB, a slight increase of 4.6% [4]. Market Trends - The internet healthcare sector in Hong Kong saw a collective rise, with notable increases in stock prices for companies like ZhongAn Online and Alibaba Health [3]. - The rapid development of AI and large models in healthcare is recognized as a key driver for competition in the industry [5]. Technological Advancements - JD Health has launched several innovative drugs and AI products, enhancing its service offerings [4][5]. - The "AI Jingyi" product system and the "Jingyi Qianxun" open-source model are significant advancements in providing intelligent diagnostic support [5]. - Over 80% of doctors in JD Health's online hospital utilize AI services, with a 91% satisfaction rate for AI nutritionist services [5]. Competitive Position - JD Health is positioned as a leader in the domestic internet healthcare market, benefiting from its supply chain capabilities and integrated online retail model [6]. - The release of the Jingyi Qianxun model is expected to further solidify JD Health's dominance as the largest online healthcare platform in China [7].

恒生指数涨2%，恒生科技指数涨2.2%。京东健康涨超6%，小鹏汽车涨超5%。 ...

汇丰：上调京东健康目标价4.65%至45港元 金十数据5月14日讯，汇丰发表报告，将京东健康(06618.HK)目标价由43港元，调高4.65%至45港元，投 资评级维持"买入"。汇丰指，京东健康首财季营收为166亿元人民币，按年增25%，按季增1%。经调整 后营业毛利率为7.9%，较去年增长2.2个百分点，较上季增长6.9个百分点，主要得益于毛利率改善。经 调整后净利率为10.6%，较去年同期上升1.6个百分点/季增5.7个百分点。该行目前预测京东健康2025年 全年营收年增17.6%至684亿元人民币，意味着2025年第二财季至第四财季按年增15%。该行预计全年经 调整后营业毛利率为4.8%，较去年增长3个百分点，non—GAAP净利润率为为7.6%，按年减0.6个百分 点。 ...

5月14日，港股三大指数集体高开，恒生指数涨0.90%，报23316.45点，恒生科指涨1.58%，国企指数涨 0.99%。盘面上，科网股普遍上涨，机器人概念股普遍高开，生物医药股普涨，汽车股普涨。近期热度 较高的恒生科技指数ETF（513180）开盘后跟随指数上涨，持仓股中，腾讯音乐、京东健康、京东集 团、阿里健康、美团等涨幅居前。 值得一提的是，本周内，腾讯控股（5月14日）、阿里巴巴（5月15日）也将陆续公布最新季度财报，相 关业绩、Capex指引和AI应用布局进展值得关注，或成本周焦点。 1） 京东健康发布2025年第一季度业绩，收入166.45亿元(人民币，下同)，同比增长25.5%；经营盈利 10.71亿元，同比增长119.8%。 公开信息显示，恒生科技指数ETF（513180）在A股上市的同赛道ETF中规模和流动性双双领先，支持 T+0交易。其标的指数软硬科技兼备，囊括中国AI核心资产以及相较于A股更为稀缺的科技龙头。外围 扰动方面迎来重磅利好，前期过度计入悲观预期的港股在情绪面上或大幅回暖，高弹性、高成长的恒生 科技或具备更大的向上动能。（场外联接A/C：013402/013403） 2） 京 ...

Group 1 - JD Health's stock rose over 6% following the release of its Q1 2025 earnings, reaching HKD 40.3 with a trading volume of HKD 145 million [1] - For Q1 2025, JD Health reported revenue of RMB 16.645 billion, a year-on-year increase of 25.5%, and operating profit of RMB 1.071 billion, up 119.8% year-on-year [1] - The company launched several innovative drugs in Q1 2025, expanding treatment options for patients [1] Group 2 - According to a report by Credit Lyonnais, JD Health's Q1 performance indicators are expected to be robust, with total revenue projected to increase by 15% year-on-year to RMB 15.3 billion [2] - The increase in revenue is attributed to heightened demand for pharmaceuticals due to a flu outbreak since January and improved user traffic from a trade-in promotion on the JD platform [2] - The report anticipates a 20% year-on-year increase in pharmaceutical sales, with health products and medical devices expected to maintain over 10% growth [2]

京东健康第一季度营收166.5亿元人民币。 第一季度经营利润10.7亿元人民币。 ...